

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESSEX BIO-TECHNOLOGY LIMITED

億勝生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1061)

VOLUNTARY ANNOUNCEMENT 2017 NATIONAL INSURANCE DRUG LIST

This is a voluntary announcement made by Essex Bio-Technology Limited (“**Company**”, together with its subsidiaries, the “**Group**”) to keep investors informed of the latest business development of the Group.

The board of directors of the Company is pleased to announce that three bio-pharmaceutical products of the Group continue to be listed on the latest National Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (“**NDL**”) issued by the Ministry of Human Resources and Social Security of the People’s Republic of China on 23 February 2017, with the reimbursement restrictions imposed on two of them previously being removed.

Details of the Group’s listed bio-pharmaceutical products are set out below:

Product series	Product form	Common name	Status
Beifushu	Eye Drops	recombinant bovine basic fibroblast growth factor (rb-bFGF)	Class B (No. 427)
Beifushu	Gel	recombinant bovine basic fibroblast growth factor (rb-bFGF)	Class B (No. 427)
Beifuji	Lyophilized Power	recombinant bovine basic fibroblast growth factor (rb-bFGF)	Class B (No. 427)

There is a change in the eligibility for seeking reimbursement for Beifuji Lyophilized Power and Beifushu Gel. Previously, under the prior version of the NDL published in 2009, only patients suffering from work-related injuries were eligible for reimbursement, but now such restriction has been lifted such that all kinds of patients (including those making general medical claims) are eligible. This change is expected to provide impetus for organic growth of the Group's flagship bio-pharmaceutical products, namely Beifushu and Beifuji, in the immediate future.

On behalf of the Board
Essex Bio-Technology Limited
Ngiam Mia Je Patrick
Chairman

Hong Kong, 7 March 2017

Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou and Mr. Zhong Sheng. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Mr. Mauffrey Benoit Jean Marie and Ms. Yeow Mee Mooi.